Baseline characteristics were similar to those of STAMP trial patients started on TB treatment after TB screening (both with and without positive TB tests), but early empirically treated patients were more severely immunosuppressed and more likely to have danger signs than STAMP trial patients not treated for TB (median CD4 count, 282 cells/ μL and 11.6% with WHO danger signs; Table 1). This evidence concerns the gene CD4 and tuberculosis.